Novel Lupus Drugs Continue to Shine in Extended Early Data

(MedPage Today) -- LONDON -- Two investigational drugs for lupus with encouraging primary phase II results yielded more good news from follow-on studies, reports here indicated. The Toll-like receptor (TLR) inhibitor enpatoran showed no diminution...
Source
MedPage Today
Opens original article in a new tab



